Literature DB >> 7689748

Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40.

F H Durie1, R A Fava, T M Foy, A Aruffo, J A Ledbetter, R J Noelle.   

Abstract

The ligand for the CD40 antigen is a 39-kilodalton protein, gp39, expressed on the surface of activated CD4+ T cells and is essential for thymus-dependent humoral immunity. The role of gp39-CD40 interactions in autoimmune disease was investigated in vivo with the use of an antibody that blocks their interactions (anti-gp39). Arthritis induced in mice by immunization with type II collagen was inhibited by anti-gp39. Anti-gp39 blocked the development of joint inflammation, serum antibody titers to collagen, the infiltration of inflammatory cells into the subsynovial tissue, and the erosion of cartilage and bone. Thus, interference with gp39-CD40 interactions may have therapeutic potential in the treatment of autoimmune disease.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7689748     DOI： 10.1126/science.7689748

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  114 in total

1.  Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system.

Authors:  R P Phipps
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

2.  Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis.

Authors:  Laurence M Howard; Serge Ostrovidov; Cassandra E Smith; Mauro C Dal Canto; Stephen D Miller
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

3.  Vascular cell adhesion molecule-1 (VCAM-1) blockade in collagen-induced arthritis reduces joint involvement and alters B cell trafficking.

Authors:  R A Carter; I K Campbell; K L O'Donnel; I P Wicks
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

4.  A polymorphic CD40 ligand (CD154) molecule mediates CD40-dependent signalling but interferes with the ability of soluble CD40 to functionally block CD154:CD40 interactions.

Authors:  B Barnhart; G S Ford; A Bhushan; C Song; L R Covey
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

Review 5.  Targeting CD40L: a promising therapeutic approach.

Authors:  Dimitris Daoussis; Andrew P Andonopoulos; Stamatis-Nick C Liossis
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

6.  CD40 glycoforms and TNF-receptors 1 and 2 in the formation of CD40 receptor(s) in autoimmunity.

Authors:  Gisela M Vaitaitis; David H Wagner
Journal:  Mol Immunol       Date:  2010-06-19       Impact factor: 4.407

Review 7.  Therapeutic potential for blockade of the CD40 ligand, gp39.

Authors:  J E Buhlmann; R J Noelle
Journal:  J Clin Immunol       Date:  1996-03       Impact factor: 8.317

8.  T cell clones from an X-linked hyper-immunoglobulin (IgM) patient induce IgE synthesis in vitro despite expression of nonfunctional CD40 ligand.

Authors:  P Life; J F Gauchat; V Schnuriger; S Estoppey; G Mazzei; A Durandy; A Fischer; J Y Bonnefoy
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

Review 9.  Immune cell signaling aberrations in human lupus.

Authors:  S N Liossis; P P Sfikakis; G C Tsokos
Journal:  Immunol Res       Date:  1998-08       Impact factor: 2.829

10.  Association of CD40 Gene Polymorphisms with Susceptibility to Neuromyelitis Optica Spectrum Disorders.

Authors:  Ziyan Shi; Qin Zhang; Hongxi Chen; Xiaohui Miao; Ju Liu; Zhiyun Lian; Huiru Feng; Hongyu Zhou
Journal:  Mol Neurobiol       Date:  2016-08-30       Impact factor: 5.590
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.